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Global left ventricular (LV) ejection fraction (LVEF) has been used as a measure of improvement in LV
function following cell therapy. Although the impact of cell therapy on LVEF in short- and long-term
follow-uphasbeengenerally positive, there is concern that researchevaluating regional therapeutics (e.g.,
cell or gene therapy) may require analysis of regional LV function localized to the site of intervention.
Regional LV assessment is traditionally performedwith qualitative or quantitative analysis of wall thicken-
ing within 16 myocardial segments, but advances in noninvasive imaging permit an increasingly more
detailed andaccurate evaluationof LV function.Wall-thicknessmeasurements cannow includeevaluation
of over 1,000 myocardial segments. In addition to higher resolution measures of wall thickening, auto-
mated assessments of myocardial segment deformation, such as strain imaging, exist. Strain imaging
allows for direct evaluation of themechanical properties thatmay improve following regional therapeutic
intervention. Improvements in regional LV functionmayalsobe assessedbydetermining regional ejection
fraction (EF). RegionalEFoffers theadvantageofsummarizingtheendresultofallof thecomplexdeformations
n theadjacentmyocardial segments. Although regional EF and strain imaging, as comparedwithwall thicken-
ng, enhance detection of improvement in complex measures of regional myocardial function, it remains
nclear whether such measures are better able to predict meaningful improvement in clinical
utcomes. (J AmColl Cardiol Img 2011;4:671–9) © 2011 by the American College of Cardiology Foundation
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672lobal left ventricular ejection fraction
(LVEF) has been used as the predomi-
nant measure to assess LV function fol-
lowing cell therapy. However, the impact
of cell therapy on LVEF in short- and long-term
follow-up has been variable. The National Insti-
tutes of Health identified clinical aspects of cell-
based therapy as an unmet area of need and estab-
lished the Cardiovascular Cell Therapy Research
Network (CCTRN). The primary goal of the
CCTRN is to conduct multiple collaborative cell
therapy clinical protocols. CCTRN investigators
recognized that many imaging-based parameters of
LV function are available to quantify the effect of
regional cell therapy, but the basis for choosing one
over another had not been critically examined.
Accordingly, the uniqueness of this document is to
review the advantages and limitations of various
noninvasive imaging modalities available to quan-
tify global and regional LV mechanical
function. From this information, we artic-
ulate why the CCTRN investigators
reached a consensus on which measures of
LV function have the potential to most
successfully predict clinically meaningful
improvement in patient outcomes after
regional therapeutic intervention. CCTRN
protocols include acquisition of cardiac
magnetic resonance (CMR) and echo im-
ages with response variables quantified at
dedicated echo and CMR core laborato-
ries with results submitted to a central data
coordinating center. Because the CCTRN
will collect many variables provided by
multiple modalities, its work should help answer
which measures of regional LV function are most
clinically relevant.
Global LV Assessment
Myocardial contraction is a complex process that
occurs in 4 dimensions in both a global and seg-
mental domain. Since segmental myocardial con-
traction has been difficult to measure in patients,
global measures to assess LV performance have
often been used. It remains unclear whether mea-
sures of global LV pump performance or regional
LV function are most predictive of cardiovascular
(CV) outcomes.
Methods of global LV assessment. Global LV func-
tion is most frequently reported as LVEF, which
refers to the percentage of the LV end-diastolic
ll
ar
ionvolume ejected with each contraction. LVEF can be sdetermined by multiple imaging modalities, includ-
ing echocardiography, ventriculography, CMR im-
aging, computed tomography, and radionuclide an-
giography. Although CMR is widely regarded as
the reference standard for measurement of LVEF,
echocardiography is most frequently used, being
inexpensive, portable, and without contraindica-
tions. However, there are limitations with echocar-
diographic assessment of LVEF. Foreshortening of
the apical views will result in an underestimate of
LV volumes and overestimate of LVEF, whereas
the presence of regional wall motion abnormalities
can lead to errors when limited imaging planes are
used to assess LVEF. Additionally, there is more
interstudy variability of LVEF with echocardiogra-
phy compared with CMR (1). Due to the different
handling of endocardial trabeculations, echocardi-
ography typically results in lower volumes than
those determined with CMR. Use of microbubbles
for contrast can significantly improve endocardial
visualization by echocardiography and provide vol-
ume estimates that more closely approximate those
determined with computed tomography (2). Three-
dimensional (3D) echocardiography can also improve
LVEF assessment, particularly in the presence of
regional dyskinesis (3). However, endocardial defini-
tion is sometimes suboptimal with 3D acquisition.
Determination of LVEF with CMR may overcome
the challenge of regional wall motion abnormalities
by utilizing a series of short-axis imaging planes
that incorporate the entire LV. However, CMR is
expensive, less widely available, and at the present
time, prohibited in patients with electronic devices.
This may limit its usefulness among patients with
advanced heart failure enrolled in cell therapy trials
who have pacemakers or defibrillators.
Applications of global LV assessment. Assessment of
lobal LVEF provides a robust predictor of risk for
V outcomes, with the potential to significantly
nfluence patient management. For example, in
eart failure patients, the risk for all-cause mortality
s increased by 39% for every 10% reduction in
VEF below 45% (4). Similarly, CV death and
eart failure hospitalization rates declined with
ncreasing LVEF up to 45%. The discriminatory
ffect of LVEF for prediction of outcomes is limited
n patients with an LVEF 45%. This lack of
iscrimination may be due to inability to detect
ubtle abnormalities of segmental LV systolic func-
ion not contained within the imaging planes used
o assess LVEF. An assessment of global LV
unction based on the composite of function in eachA B B R E V I A T I O N S
A N D A C R O N YM S
CCTRN Cardiovascular Ce
herapy Research Network
MR cardiac magnetic
resonance
CV cardiovascular
EF ejection fraction
LV left ventricle/ventricul
LVEF left ventricular eject
fraction
STE speckle trackingegment has the potential to overcome these limi-
t
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673tations and is superior to LVEF in predicting risk
for adverse outcome (5). It is noteworthy that the
LVEF in many patients enrolled in CV cell therapy
trials exceeds this 45% threshold (6).
Although global LVEF may improve after inter-
vention, such improvements may be subtle. LVEF
improved only 1% to 5% in patients with otherwise
evidence-documented life-saving therapies (e.g.,
coronary revascularization, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockade,
or beta blockade) after acute myocardial infarc-
tion (7). Thus, small changes in LV function may
translate to meaningful improvement in clinical
outcomes, but global LVEF may be an insensitive
measure of this change in outcome. This is
supported by the findings in the REPAIR-AMI
(Reinfusion of Enriched Progenitor Cells and Infarct
Remodeling in Acute Myocardial Infarction) study,
which demonstrated that adverse outcomes were sig-
nificantly reduced among patients receiving cell ther-
apy compared with placebo, despite only a small
improvement in LVEF (6).
As compared with revascularization alone, addi-
ional improvements in LVEF after cell therapy and
evascularization have ranged from 0% to as much
s a 6% (Table 1) (8–13). If global LVEF is to be
used as the measure of interest in cell therapy trials,
use of an imaging modality that limits need for
geometrical or 3D assumptions, such as with CMR
or 3D echocardiography, would be preferred. How-
ever, important, but subtle, changes in LV function
after cell therapy may not be detected with global
assessment of LV function, whereas regional assess-
ment of LV function may enhance detection of
these important changes.
Table 1. Selected Cell Therapy Trials Evaluating Changes in Bot
Trial Name, First Author, Year (Ref. #)
No. Patients
Randomized
BOOST, Wollert et al., 2004 (13)
and Meyer et al., 2006 (12)
60 CM
CM
ASTAMI, Lunde et al., 2006 (10)
and Beitnes et al., 2011 (8)
100 Ec
CM
Sp
Meluzin et al., 2006 (11) 66 SP
Lo
Herbots et al., 2009 (9) 67 Ec
TD
*All studies included in this table were in the setting of acute ischemia with in
ASTAMI  Autologous Stem Cell Transplantation in Acute Myocardial Infarction;
EF  ejection fraction; long.  longitudinal; LV  left ventricular; SPECT  single-photRegional LV Assessment
Regional LV assessment can include evaluation of me-
chanical function, segmental perfusion, and tissue char-
acterization. Segmental perfusion and tissue characteris-
tics are important components of regional myocardial
function after acute ischemic injury, as the presence of
microvascular obstruction and the ratio of edematous to
infarcted tissue predict improvement in contractile func-
tion and future CV events (14–16). However, due to
space limitations, the current review focuses on measures
of mechanical function. Assessment of regional LV me-
chanical function can be performed with quantification
of both regional EF or segmental myocardial contraction.
Regional EF offers the advantage of summarizing the
end effect of the complex deformations in adjacent
myocardial segments, whereas quantification of segmen-
tal myocardial contraction allows for direct evaluation of
mechanical properties of selected myocardial segments
that may be improved following cell therapy.
Regional EF. Regional EF has been determined with
nuclear, CMR, and echocardiographic techniques
(17,18), and with each imaging modality, has been
defined by different methods. For example, regional
EF measured with CMR can be as simple as the
comparison of the end-diastolic and end-systolic vol-
umes constrained by the endocardial border in a single
short-axis CMR image. This method was employed
in the BOOST (BOne marrOw transfer to enhance
ST-elevation infarct regeneration) trial as regional EF
was determined only in slices that contained late
contrast enhancement (13). Other studies have re-
ported regional EF using the fixed centerpoint
method. Briefly, the ventricle is divided into a number
of wedge-shaped subvolumes radiating from the LV
lobal and Regional LV Function*
aging Variable
Follow-Up
Duration
Change in Imaging
Cell-Treated Patients
Imaging Variable in Control
lobal EF 6 months Improved 6% (p 0
18 months Improved 2.8% (p
egional EF 6 months Improved 5.7% (p
Simpson) global EF 6 months Improved 0.6% (p
lobal EF 6 months Worsened 3% (p
e echo long. strain 3 years Improved 0.4% (p
global EF 3 months Improved 3% (p 0
strain rate 3 months Improved 0.9 cm/s
Simpson) global EF 4 months Worsened 1.5% (p
ho long. strain 4 months Improved 3.7% (p
ronary delivery of cells.
T  BOne marrOw transfer to enhance ST-elevation infarct regeneration; CMR  cah G
Im
Variable in
vs. Change in
s “Treatment Effect”
R g .0026)
0.27)
R r 0.04)
ho ( 0.7)
R g 0.054)
eckl 0.45)
ECT .041)
ng. (p 0.008)
ho ( 0.84)
I ec 0.01)
traco
BOOS rdiac magnetic resonance;on emission computed tomography; TDI  tissue Doppler imaging.
D’Hooge et al. (23).
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674long axis, and the proportional change in each subvol-
ume from diastole to systole is reported as the regional
EF. Finally, the CCTRN CMR core laboratory divides
the LV volume into thirds and measures the end-
diastolic and end-systolic volume within each of the
apical, mid, and basal regions.
Regional EF strongly correlates with the function
of adjacent myocardial segments as determined by
wall motion, wall thickening, and infarct transmural-
ity. Thus, regional EF measured by CMR in acute
myocardial infarction patients was significantly lower
in regions with infarction versus regions with no
infarction in adjacent myocardial segments (17).
Regional EF measured with radionuclide ventricu-
lography has been shown to improve with revascular-
ization (19). Additionally, regional EF measured by
CMR did improve after revascularization for acute
myocardial infarction, whereas wall thickening did not
(17). Regional EF may also be a sensitive marker of
improvement after cell therapy. In the BOOST trial,
patients who received intracoronary bone marrow cells
had significant improvement in regional EF at 6
months compared with those who did not receive cells
(13). However, this difference was not present at 18
months, largely due to delayed improvement in re-
gional EF in the control group (12). In BOOST,
regional EF and global EF improved in a similar
degree in patients with cell therapy. Therefore, al-
though regional EF appears more sensitive than wall
thickening in detection of improved LV function after
traditional revascularization, it remains unclear
gonal Axes of the Left Ventricle
the orientation of the 3 types of myocardial segmental deforma-
eported with strain imaging. Adapted, with permission, fromwhether regional EF will advance detection of im-
proved LV function following cell therapy.
Segmental myocardial contraction. Assessment of re-
gional myocardial function can be improved by char-
acterization of segmental deformation throughout the
heart. This is complicated because the LV has a
complex architecture with a left-handed helix in the
epicardium, a right-handed helix in the endocardium,
and nearly circumferential fibers in the midwall (20).
This architecture leads to 4 contraction patterns dur-
ing systole: radial wall thickening; circumferential
contraction; descent of the base of the heart toward
the apex with longitudinal shortening; and torsion, as
epicardial helical fibers rotate the apex counterclock-
wise (as viewed from the apex) relative to the base
(21). There are numerous methods for quantifying
each of these, but it is unclear which will prove most
accurate for characterizing the response to cell therapy.
Among the oldest methods to quantify radial wall
thickening is the centerline method, which measures
myocardial thickening relative to the center of the wall
(22). Wall thickening is traditionally reported as
average thickening within each of the American Heart
Association 16 or 17 segments. However, the higher
resolution afforded by advanced noninvasive imaging
techniques, such as CMR, coupled with increased
processing power for image reconstruction and anal-
ysis, provide new opportunities. For example, the
CCTRN CMR core laboratory has chosen to analyze
8 to 12 short-axis slices with 100 chords per slice. As
a result, approximately 1,000 chords are analyzed for
each study, with wall thickening and motion calcu-
lated for each chord using the centerline method.
Methods of strain imaging. A more advanced ap-
proach to describe regional contraction is through
use of strain imaging, which characterizes myocar-
dial tissue deformation. Mathematically, strain is a
3  3 tensor, which captures both linear deforma-
tion (stretching or compression along the 3 princi-
pal axes) and shear (sliding of 1 tissue plane against
another). In the heart, strain is typically referenced
to the coordinate system of the LV, yielding radial,
circumferential, and longitudinal strain components
(23) (Fig. 1). In addition to these 3 components of
myocardial segment deformation, strain imaging
allows for quantification of LV torsion, which is an
important component of normal LV mechanics
(24). Regional EF correlates strongest with circum-
ferential and longitudinal strain compared with wall
thickening, suggesting that these parameters may
have a greater impact on stroke volume and cardiacFigure 1. The 3 Ortho
Diagram demonstrates
tion most commonly routput than wall thickening alone (25).
n b
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675CARDIAC MAGNETIC RESONANCE. The most fre-
quent approach to CMR strain imaging is by
tracking a grid of magnetic tags formed by inverting
protons in specific locations throughout the image
(26). Radiofrequency tagging is accomplished by
altering the net magnetization of the tissue with
carefully designed radiofrequency pulses (27). Each
tag is created as a 3D plane that extends through
the tissue, and it is seen as a dark line (Fig. 2).
Because these tags result from alterations of mag-
netization of tissue itself, the motion of the tags
matches the motion of underlying tissue, which can
be tracked over time to quantify myocardial defor-
mation. Wall thickening determined by tagged
CMR correlates with wall-thickening measures by
sonomicrometry, although systolic thickening ap-
pears to be systematically higher with tagged CMR
versus sonomicrometry (Table 2) (17,18,28–34).
Figure 2. Example of Cardiac Magnetic Resonance Tagging
The tags are seen as dark lines. The deformation of the tag lines ca
Table 2. Accuracy and Precision of Measures of Global and Reg
Reference Standard Cor
Estimate of global EF
Echocardiography (29,33) CMR
CMR (29,34) Echo
Ventriculography (33) Echo
RNA (33) Echo
Estimate of regional EF
Echocardiography (31) Not available
CMR (17) Not available
RNA (18) Not available
Estimate of segmental contraction
CMR–radial strain (30,32) Sonomicrometry
STE–radial strain (28) Sonomicrometry
Bland-Altman limits of agreement were not available for all modalities and are
COR  coefﬁcient of repeatability; diff.  difference; RNA  radionuclide angiograECHOCARDIOGRAPHY. Unfortunately, CMR strain
measurements are rarely made in clinical practice,
due to cost, lengthy time of analysis, and contrain-
dications for patients with implanted devices.
Echocardiography can be used to calculate regional
myocardial strain by 2 basic techniques: analysis of
velocity from tissue Doppler and tracking of myocar-
dial speckles. Tissue Doppler maps the component of
velocity directed toward the transducer throughout the
image. The spatial derivative of velocity along the scan
line yields the strain rate, the temporal integral of
which yields strain (35). However, this technique is
dependent on alignment of the ultrasound beam in
the appropriate region of interest. Therefore, only
certain axes of deformation can be determined in a
limited number of myocardial segments.
Speckle tracking echocardiography (STE) over-
comes many limitations of tissue Doppler techniques.
e seen at end-systole.
l LV Function
tion With Reference Standard Intraobserver Reliability Inte
r 0.41 4.4% mean diff.
r 0.41 Not available
r 0.85 4.3% mean diff.
r 0.86 2.5% mean diff.
4.9% mean diff.
1.6% mean diff.
r 0.63–0.93
r 0.87 r 0.69–0.77
r 0.79 COR 4.6%
efore not included.iona
rela robserver Reliability
6.1% mean diff.
Not available
6.7% mean diff.
6.8% mean diff.
5.8% mean diff.
1.9% mean diff.
r 0.6–0.98
r 0.57–0.71
COR 7%
ther
phy; STE  speckle tracking echocardiography; other abbreviations as in Table 1.
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676STE is based on tracking fairly constant speckle
patterns created by interference of the ultrasound
beam with microscopic structures within the myocar-
dium (28). Because STE analyzes routinely acquired
grayscale images, it is, unlike tissue Doppler, angle
independent and can be quickly and reproducibly
performed offline after study completion. STE allows
strain and strain rate measurement along all 3 orthog-
onal axes of ventricular deformation for all LV seg-
ments. Both tissue Doppler and STE modestly cor-
relate with CMR tagging and sonomicrometry
(28,36). However, image quality, frame rate, and
depth and direction of movement of the tracked
speckles can impact fidelity of the analysis. At times as
much as 10% to 20% of data in a single study may be “too
noisy” for appropriate analysis (37,38). Recently, STE
has been applied to 3D echocardiograms (39). Whether
the advantage of being able to track speckles wherever
they move in 3D space outweighs the much lower frame
rate of 3D echo and associated further impairment in the
fidelity of the analysis, remains to be determined.
A limitation of both 2D and 3D STE is that it is
very vendor specific, typically applied to images
stored in proprietary ultrasound scan line formats.
There are limited data demonstrating equivalence
between strain measurements obtained by different
vendors. The American Society of Echocardiogra-
phy and the European Association of Echocardiog-
raphy have formed a task force with industry to
address these concerns, and hopefully, this will
make STE more widely applicable to images stored
in standard Digital Imaging and Communications
in Medicine format.
Applications of strain imaging in ischemic heart disease.
These newer measures of segmental myocardial
contraction have been used in many different ways
haracteristics of Different Imaging Techniques for Various Applic
/Technique (Ref. #) Referen
ualitative wall motion (40) 50% stenosis on angiography
ualitative wall motion (41) 50% stenosis on angiography
gitudinal strain (41) 50% stenosis on angiography
recovery after revascularization
perenhancement (37) Visually determined improvemen
train (37) Visually determined improvemen
e after acute Injury
CMR determined infract size 20
(43) CMR determined infarct size 20
eling after acute injury
ain (42) Increase in LV end-diastolic volumse; IHD  ischemic heart disease; LVEF  left ventricular ejection fraction; MI  myocardial into evaluate patients with ischemic heart disease.
Echocardiographic and CMR strain imaging may
assist with identification of ischemic tissue (Table 3)
(37,40–43). Additionally, strain imaging provides
estimation of segmental myocardial viability and
likelihood of improvement with revascularization
(37). Furthermore, strain imaging has demon-
strated the ability to predict final infarct size and
LV remodeling after infarction (42,43). Therefore,
strain analysis may assist in identifying those patients
who would benefit from an early, invasive strategy that
includes revascularization and/or cell therapy. Impor-
tantly, strain imaging may increase the sensitivity to
detect improvement of LV function after regional
therapy and may enhance localization of infarcted
tissue that might benefit from such therapy.
Markers of improved function after cell therapy. As-
essment of improvement in LV function after cell
herapy may be a more difficult task than simply
ssessing a change in overall LVEF. This may be
articularly true in the setting of acute myocardial
nfarction where hyperdynamic contraction of re-
ote regions may elevate LVEF. Quantified mea-
ures of LV segmental myocardial strain may allow
or better recognition of these early and subtle
mprovements in myocardial function in the peri-
nfarct region following cell therapy. For example,
arly after reperfusion for acute myocardial infarc-
ion, there was no significant difference in the
mprovement in LVEF comparing patients treated
ith cells and controls (9). However, strain of
nfarcted segments improved significantly more in
he cell-treated group. In another pilot study, 12
atients who received intramyocardial autologous
ells during coronary artery bypass surgery were
valuated with echocardiography before and 1 year
ns in Patients With IHD
Standard Sensitivity Speciﬁcity
83% 83%
76% 93%
84% 88%
segmental contraction after revasc. 72% 92%
segmental contraction after revasc. 70% 85%
f LV mass 80% 55%
f LV mass 90% 86%
f 15% 3 months after acute MI 91% 86%Table 3. Operating C atio
Application ce
Prediction of CAD
Dobutamine CMR–q
Dobutamine echo–q
Dobutamine STE–lon
Viability/prediction of
CMR–gadolinium hy t in
Resting STE–radial s t in
Prediction of infarct siz
LVEF (43) % o
STE–LV global strain % o
Prediction of LV remod
STE–longitudinal str e ofarction; revasc.  revascularization; other abbreviations as in Tables 1 and 2.
M
H
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677after injection (44). On average, longitudinal strain
increased 40% in segments that underwent revas-
cularization without cell therapy, but increased 93%
in segments that underwent revascularization with
cell therapy (p  0.002). In cell-treated segments,
visual estimates of segmental myocardial contractil-
ity increased 5%, whereas longitudinal strain in-
creased 159% (p 0.0001). Although these explor-
atory studies suggest that strain imaging may be
more sensitive in detecting improvement in LV
function after cell therapy, not all studies have
demonstrated strain to be superior to LVEF as a
marker of improvement after cell therapy. In the
ASTAMI (Autologous Stem Cell Transplantation in
Acute Myocardial Infarction) trial, improvements
in LVEF and longitudinal strain were no different in
cell-treated patients compared with those who re-
ceived placebo (8). In this study, strain measurements
may not have improved because of the lack of true
improvement in myocardial function. Future studies
comparing the ability of strain and LVEF to detect
improvement following cell therapy are clearly needed.
As reported above, regional EF may also be a
sensitive marker of improvement in LV function
after cell therapy. Because comparative studies are
lacking, it remains unclear whether regional EF or
strain will be the most sensitive measure of im-
proved LV function after cell therapy. Also un-
known are the amounts and types of improvements
in these regional measures of LV function that
might predict improvements in morbidity and mor-
tality. For example, is improvement in apical re-
gional EF or strain more relevant than improve-
ment in basal regional LVEF or strain? Data from
the CCTRN core labs could help answer these
questions.
Conclusions and Future Directions
Although the impact of cell therapy on global
Table 4. Goals for Imaging Variables in Future Cell Therapy Tria
Measurement of global LV function should rely on imaging modalit
CMR or 3D echocardiography.
When feasible, regional LV function should be incorporated into en
Small studies suggest that myocardial strain has an improved ability
Compared with wall thickening, regional EF may be a more sensitiv
Regional analysis may reduce the inﬂuence of hyperdynamic rem
Measurement of global and regional LV function should be safe an
1 to 2 years following cell therapy administration.
In AMI cell therapy trials, baseline measurements of regional and g
to minimize the effects of myocardial stunning resolution.
3D  3-dimensional; AMI  acute myocardial infarction; other abbreviations aLVEF in short- and long-term follow-up has been Evariable, overall, the results show modest improve-
ment. To better assess the effect of regional thera-
peutics (such as cell or gene therapy), we propose
that future research include analysis of regional LV
function localized to the site of intervention (Table 4).
Regional LV mechanical function can be quantified
with regional EF or measures of segmental myo-
cardial contraction. Segmental contraction can be
evaluated by indices of wall thickening or with
CMR or echocardiographic strain imaging.
Changes in regional EF and myocardial segmen-
tal strain appear to offer an enhanced ability to
detect subtle improvements in LV function after
intervention. Although regional EF and strain,
compared with wall thickening, may enhance sen-
sitivity for detecting improvement in LV function,
it remains unclear whether such measures are better
able to predict improvement in clinical outcomes.
Accordingly, the CCTRN will implement use of
high-definition wall-thickening measurements in
addition to regional EF measurements. The
CCTRN will consider incorporating strain imaging in
future projects, and will aim to determine which
measures of regional LV mechanical function best link
with clinical outcomes. Further, assessment of LV
function after cell therapy may not be appropriately
addressed with a single measure of a single region.
Assimilation of all of the regional information pro-
vided to the CCTRN central data coordinating center
should allow for the investigation of new indices or
computational models to help better understand the
impact of cell therapy on LV function.
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that limit need for geometrical or 3D assumptions, such as with
int analysis of LV function.
etect improvement in myocardial contraction after cell therapy.
rker of improvement in LV function after regional intervention.
myocardial regions that may inﬂate global LVEF following AMI.
latively affordable to allow serial evaluation of LV function over
l LV function should be performed at a standardized time point
ables 1 and 3.ls
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